NewAmsterdam Pharma Company N.V. reported third-quarter 2026 financial results, recognizing $19.2 million in revenue driven by regulatory milestone payments from partner Menarini, compared to $0.3 million in the prior-year period. The company recorded a net loss of $17.4 million, narrowing significantly from a $72.0 million loss in Q3 2025, as research and development expenses rose to $39.4 million and selling, general, and administrative costs decreased slightly to $24.0 million. As of September 30, 2026, the company held $643.1 million in cash, cash equivalents, and marketable securities. The filing also highlighted that the European Commission granted marketing authorization for Ubeslo and Evlarco, marking the first global regulatory approval for obicetrapib, while noting the initiation of the SPINOZA Phase 2b trial for Alzheimer's disease and planned PREVAIL interim analysis results in early 2027. NewAmsterdam Pharma is a late-stage biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL-C.
